Medpace Holdings, Inc. MEDP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| AVAI | $38.02M-0.6% | $38.25M+4.7% | $36.52M+25.5% | $29.11M-6.3% | $31.06M-10.8% | |
| Cardiology | $80.21M+9.6% | $73.18M+11.5% | $65.63M+7.4% | $61.13M+11.3% | $54.9M+11.5% | |
| Central Nervous System | $56.26M-10.8% | $63.04M+6.0% | $59.47M+1.5% | $58.58M+0.5% | $58.28M0.0% | |
| Metabolic | $201.24M+2.7% | $195.92M+1.7% | $192.64M+2.2% | $188.56M+10.6% | $170.48M+1.4% | |
| Oncology | $237.56M-4.9% | $249.81M+25.4% | $199.26M+34.7% | $147.87M-0.1% | $148.02M+20.5% | |
| Other | $93.32M+5.7% | $88.25M-17.1% | $106.4M-9.9% | $118.06M+23.2% | $95.84M-7.1% | |
| Total direct costs by Product | ||||||
| Direct Costs | $198.27M+8.9% | $182.15M-2.2% | $186.34M+0.3% | $185.83M+4.5% | $177.82M+6.1% | |
| Reimbursed out-of-pocket expenses | $312M-2.8% | $320.98M+16.0% | $276.63M+16.5% | $237.47M+17.3% | $202.4M+6.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medpace Holdings, Inc. break its business down?
- Medpace Holdings, Inc. (MEDP) reports total revenue by product across 6 parts — AVAI, Cardiology, Central Nervous System, Metabolic and Oncology. Each is extracted from the segment footnotes and tracked over time.
- Where does Medpace Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medpace Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
